Proceedings of the Final Congress of COST Action B25 : Physiologically Based Pharmaco-Toxicokinetics and Dynamics, held in Athens, 26–27 May 2009
Variability and Impact on Design of Bioequivalence Studies
Physiologically Based Modelling and Prediction of Drug Interactions
Predicting Drug Disposition via Application of a Biopharmaceutics Drug Disposition Classification System
Biopharmaceutical Classification Based on Solubility and Dissolution : A Reappraisal of Criteria for Hypothesis Models in the Light of the Experimental Observations
Mode of Action Considerations in the Quantitative Assessment of Tumour Responses in the Liver
Modelling of Drug Disposition Kinetics in In Vitro Intestinal Absorption Cell Models
An Integrated Model for the Glucose-Insulin System
On Setting the First Dose in Man : Quantitating Biotherapeutic Drug-Target Binding through Pharmacokinetic and Pharmacodynamic Models
Pharmacodynamic Effects of Haematopoietic Cytokines : The View of a Clinical Oncologist
Active-Site Concentrations of Chemicals – Are They a Better Predictor of Effect than Plasma/Organ/Tissue Concentrations?
The New European Medicines Agency Guideline on the Investigation of Bioequivalence
Sex Differences in Animal Models of Depression and Antidepressant Response
Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy : Evaluation of Predicted Outcome with Different Types and Amounts of Information
Pharmacodynamic Effects in the Cardiovascular System : The Modeller's View
Optimal Design of Pharmacokinetic Studies
Physiologically Based Pharmacokinetic/Pharmacodynamic Animal-to-Man Prediction of Therapeutic Dose in a Model of Epilepsy
Predictable and Less Predictable Unwanted Cardiac Drugs Effects : Individual Pre-Disposition and Transient Precipitating Factors